AtriCure, Inc.

AtriCure, Inc. is a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The company operates in the medical device industry, focusing on cardiac ablation and LAA management products used in both open-heart and minimally invasive surgical procedures, as well as pain management solutions for cardiac, thoracic, and amputation surgeries. Afib is described as a growing epidemic affecting over 59 million people worldwide, with over one million diagnoses annually in the United States alone. The prevalence of Afib increases with age, suggesting a growing patient population globally. The company estimates that over 500,000 patients undergoing open-heart surgery globally each year are potential candidates for surgical ablation using their products, with less than 15% currently being treated, indicating a significant growth opportunity. Additionally, Afib is responsible for approximately 15% to 20% of the estimated 800,000 strokes annually in the United States, with 90% of clots originating in the LAA, further highlighting the market opportunity for LAA management. The market for pain management ablation products also represents a significant growth opportunity, with approximately 150,000 thoracic procedures and 250,000 cardiothoracic procedures performed annually in the United States.

AtriCure positions itself as the market leader in the surgical treatment of Afib and LAA management, and a pioneer in the application of Cryo Nerve Block for pain management in cardiac, thoracic, and amputation surgical procedures. The company states that its AtriClip system is safer, more effective, and easier to use than other products for LAA exclusion. In the cardiac surgery market, Medtronic, plc is identified as a primary competitor, offering surgical ablation products and LAAM devices. For standalone Afib treatment, several companies offer endocardial catheter devices, which AtriCure views as complementary to its Hybrid AF Therapy, as its products improve outcomes for non-paroxysmal Afib when combined with these catheters. The company is monitoring other companies conducting clinical trials for persistent and long-standing persistent Afib treatment, but is not aware of any ongoing FDA trials by competitors for long-standing persistent Afib ablation. In the post-operative pain market, AtriCure is not aware of other U.S. companies pursuing cryo nerve block therapies, though some international companies market similar devices.

The company generates revenue primarily from the sale of medical devices, categorized into open ablation, minimally invasive ablation, pain management, and appendage management. Revenue is recognized at the point of shipment or delivery. The business model involves direct sales forces in the United States, Germany, France, the United Kingdom, the Benelux region, Australia, and Canada, with transactions primarily in USD, Euros, British Pounds, Australian Dollars, or Canadian Dollars. Distributors are used in other international markets, including Asia and South America. The company places capital equipment, such as RF and cryo generators, with direct customers and sells disposable handpieces.

The product portfolio is segmented into four main categories. Open ablation products, including Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices, use RF energy to create scar tissue. The Isolator Synergy Ablation System is FDA-approved for persistent and long-standing persistent Afib concomitant to other open-heart procedures. The EnCompass clamp, launched in 2022, is indicated for cardiac soft tissue ablation and aims to increase efficiency in concomitant surgical ablations. The EnCapture clamp, a new configuration of the Isolator Synergy platform, received 510(k) clearance in 2024. The cryoICE Cryoablation System is used in both open ablation and cryoanalgesia, consisting of a generator and disposable probes. In 2025, open ablation revenue was $143,847 thousand ⁴.

Minimally invasive ablation products include the EPi-Sense Systems, which utilize monopolar RF energy for tissue coagulation. The EPi-Sense System received FDA PMA approval in 2021 for symptomatic, drug-refractory, long-standing persistent Afib when augmented with an endocardial ablation catheter. The EPi-Sense ST Guided Coagulation System was approved via PMA supplement in late 2022. In 2024, FDA granted 510(k) clearance for EPi-Ease, a Hybrid access device. Minimally invasive ablation revenue was $31,475 thousand ⁵ in 2025.

Pain management products include cryoSPHERE probes and cryoXT probes. cryoSPHERE probes apply cryogenic energy to peripheral nerves for temporary pain relief, cleared for managing pain by temporarily ablating peripheral nerves. In 2024, two new cryoSPHERE probes, cryoSPHERE+ and cryoSPHERE MAX, were launched, with cryoSPHERE MAX reducing freeze times by 50% compared to the first generation. The cryoICE cryoXT probe, cleared by FDA in April 2025 and launched in September 2025, is designed for Cryo Nerve Block therapy in amputation patients. Pain management revenue was $81,923 thousand ⁶ in 2025.

Appendage management products primarily consist of the AtriClip LAA Exclusion System, designed to mechanically clamp the LAA from outside the heart. The AtriClip devices are the most widely sold LAA management devices worldwide, with over 750,000 patients treated. In 2024, the AtriClip FLEX-Mini device was launched, and in Q1 2025, FDA granted 510(k) clearance for the AtriClip PRO-Mini LAA Exclusion System. Appendage management revenue was $178,127 thousand ⁷ in 2025. The company also sells other enabling technologies like the LARIAT System for soft-tissue closure, Lumitip dissector, Glidepath guides, Subtle Cannulas, and reusable cardiac surgery instruments.

For the fiscal year ended December 31, 2025, AtriCure reported total revenue of $534,528 thousand ⁸. Cost of revenue was $133,749 thousand ⁹, resulting in a gross profit of $400,779 thousand ¹⁰ and a gross margin of 75.0% ¹¹. Operating expenses totaled $410,226 thousand ¹², comprising research and development expenses of $99,209 thousand ¹³ and selling, general and administrative expenses of $311,017 thousand ¹⁴. This led to a loss from operations of $(9,447) thousand ¹⁵ and an operating margin of (1.8)% ¹⁶. Net loss for the period was $(11,448) thousand ¹⁷, with basic and diluted net loss per share of $(0.24) ¹⁸. Cash and cash equivalents stood at $167,428 thousand ¹⁹ as of December 31, 2025. Total debt, classified as long-term, was $61,865 thousand ²⁰.

Comparing 2025 to 2024, worldwide revenue increased by 14.9% ²¹ as reported, or 14.4% on a constant currency basis. This growth was driven by open ablation, appendage management, and pain management product lines. Open ablation revenue increased by $20,200 thousand ²², or 16.3% ²³, from $123,647 thousand in 2024 to $143,847 thousand in 2025. Pain management revenue grew by $20,079 thousand ²⁴, or 32.5% ²⁵, from $61,844 thousand to $81,923 thousand. Appendage management revenue increased by $26,539 thousand ²⁶, or 17.5% ²⁷, from $151,588 thousand to $178,127 thousand. In contrast, minimally invasive ablation sales declined by $14,262 thousand ²⁸, or 31.2% ²⁹, from $45,737 thousand to $31,475 thousand, attributed to a reduction in Hybrid procedures as physicians adopt PFA catheters. International revenue increased by 20.2% ³⁰ as reported, or 17.5% on a constant currency basis. Gross margin increased by 29 basis points, from 74.7% in 2024 to 75.0% ¹¹ in 2025, due to a more favorable product mix, partially offset by increasing product costs and less favorable geographic mix. Research and development expenses increased by $3,031 thousand ³¹, or 3.2% ³², primarily due to higher personnel costs and clinical trial expenses for the LeAAPS and BoxX-NoAF trials, partially offset by a $6,000 thousand ³³ decrease in PFA co-development agreement payments. Selling, general and administrative expenses increased by $19,658 thousand ³⁴, or 6.7% ³⁵, mainly due to higher personnel costs and operational growth. Net loss improved from $(44,698) thousand ¹⁷ in 2024 to $(11,448) thousand ¹⁷ in 2025.

During 2025, AtriCure achieved several operational milestones. In Q1 2025, FDA granted 510(k) clearance for the AtriClip PRO-Mini LAA Exclusion System, which was launched in the U.S. in H2 2025. In Q2 2025, FDA granted 510(k) clearance for the cryoICE cryoXT probe, launched in the U.S. in Q3 2025. The company also executed successful first-in-human treatments using its novel dual energy platform integrating Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA) in Q4 2025. In clinical science, trial enrollment for the LeAAPS IDE clinical trial was completed in July 2025, with 6,573 patients across 139 centers globally. The first patient enrollment for the BoxX-NoAF IDE trial was completed in October 2025, following FDA protocol approval in Q4 2024. The ICE-AFIB clinical trial finished twelve-month patient follow-up in May 2024, with primary results published in 2025. The CEASE-AF three-year outcomes abstract was accepted for presentation at the 2025 European Heart Rhythm Association (EHRA) meeting. In August 2025, the company transferred legal ownership of a building and certain real property on its corporate headquarters campus for $6,250 thousand ³⁶ cash consideration, simultaneously entering into a leaseback agreement.

AtriCure's strategic priorities for future growth are centered on new product and procedure innovation, continued investments in clinical science, building physician and societal relationships, providing comprehensive training and education, and evaluating acquisition opportunities. The company anticipates that substantially all of its revenue for the foreseeable future will come from current products or those in development.

A major growth area is new product and procedure innovation, with a focus on extending and improving existing products and developing new technologies and procedural techniques. A significant development is the successful first-in-human treatments using a novel dual energy platform integrating Pulsed Field Ablation (PFA) with Advanced Radiofrequency Ablation (Advanced RFA) in the fourth quarter of 2025. This platform aims to combine the safety and effectiveness of RF ablation with the efficiency of PFA. The company expects to initiate a clinical trial for this dual energy platform in the coming year, marking a key milestone in its product development pipeline. Additionally, the launch of the AtriClip PRO-Mini LAA Exclusion System in the second half of 2025, following 510(k) clearance in Q1 2025, is expected to enhance minimally invasive LAA management with its smaller profile, offering enhanced visualization and access for surgeons. The cryoICE cryoXT probe, launched in Q3 2025 after Q2 2025 510(k) clearance, is specifically designed for Cryo Nerve Block therapy in amputation patients, expanding the pain management market.

Investments in clinical science are a critical growth vector, aimed at validating long-term results, supporting expanded indications, and increasing demand for products. The LeAAPS IDE clinical trial, which completed enrollment of 6,573 patients ³⁷ across 139 centers globally ³⁸ in July 2025, is evaluating the AtriClip LAA Exclusion System for prophylactic stroke prevention in cardiac surgery patients without pre-operative Afib. This trial has a minimum follow-up period of five years post-procedure. The BoxX-NoAF IDE trial, which completed its first patient enrollment in October 2025, aims to demonstrate the safety and effectiveness of concomitant ablation with the EnCompass clamp and AtriClip system in non-Afib patients for reducing post-operative Afib (POAF) and clinical Afib. This multi-center, multi-national randomized trial plans to enroll up to 960 subjects ³⁹ at up to 75 sites globally ⁴⁰ with follow-up through three years. If successful, this trial could significantly expand the addressable market for concomitant ablation and LAAM to include non-Afib patients undergoing cardiac surgery. The HEAL-IST clinical trial, approved by FDA in February 2022, is studying the Isolator Synergy Surgical Ablation System for inappropriate sinus tachycardia, with enrollment ongoing for up to 142 patients ⁴¹ at up to 40 sites ⁴² in the U.S., UK, and EU. The company plans to present results from long-term patient follow-up in multiple studies at 2026 meetings.

Operationally, the company's gross margin increased by 29 basis points in 2025, driven by a more favorable product mix, which offset increasing product costs and a less favorable geographic mix. Research and development expenses increased by $3,031 thousand ³¹, or 3.2% ³², primarily due to personnel costs and clinical trial expenses, partially offset by a $6,000 thousand ³³ decrease in PFA co-development agreement payments. Selling, general and administrative expenses increased by $19,658 thousand ³⁴, or 6.7% ³⁵, mainly due to headcount growth and higher variable and share-based compensation, along with $1,629 thousand ⁴³ in IT and corporate expenses due to operational growth. The company continues to invest in facilities to support growth, including an expansion of the Mason Manufacturing Building from 38,500 square feet to approximately 103,500 square feet ⁴⁴ for additional manufacturing and office space.

Planned capital allocation includes ongoing capital expenditures to support growth and customer service. The company expects to disburse between $10,000 thousand and $12,000 thousand ⁴⁵ in fixed and variable costs for the LeAAPS clinical trial within the next twelve months. Additionally, between $6,000 thousand and $8,000 thousand ⁴⁶ is expected to be disbursed within the next twelve months for contingent consideration payments related to the exclusive licensing agreement for PFA technology, upon achievement of specified developmental and regulatory approval milestones. The company's Credit Agreement was amended on January 9, 2026, extending its term by three years to January 9, 2029, and reducing the overall interest rate on loans. The applicable margin on borrowings will adjust from 1.25% to 1.50% per annum ⁴⁷ for ABR borrowings and from 2.25% to 2.50% per annum ⁴⁸ for SOFR term borrowings. The minimum utilization financial covenant was also removed.

The company explicitly flags several structural headwinds and execution risks. A prolonged downturn in macroeconomic conditions, including inflationary pressures and interest rate increases, could adversely impact procedure volumes, hospital staffing, and demand for products. Government and private payors' efforts to contain or reduce healthcare costs, including reimbursement for procedures, could harm the ability to promote and sell products. Adverse changes in payors' policies, including denials for off-label uses, could reduce revenue. International operations face risks from differing regulatory requirements, political and economic instability, and currency exchange rate fluctuations. The company relies on single and limited source third-party suppliers and sterilizers, making it vulnerable to supply problems and price fluctuations. Disruptions at its highly centralized manufacturing facilities could increase expenses and decrease revenue. Failure to properly manage anticipated growth, including increasing production output and recruiting/retaining skilled personnel, could also negatively impact the business.

The company faces material risks including the potential for a prolonged macroeconomic downturn due to inflationary pressures, increased interest rates, and slower economic activity, which could reduce revenue and adversely affect operations and cash flows. Competition from existing and new products, including catheter-based ablation and other surgical devices, may decrease market share and cause revenue decline, potentially rendering current products obsolete. Clinical trials are expensive and have uncertain outcomes, with negative data or failure to meet regulatory requirements potentially slowing adoption or reducing product use. Reliance on single and limited source third-party suppliers for manufacturing and sterilization creates vulnerability to supply problems and price fluctuations, with potential for significant delays and increased costs if alternative suppliers are needed. The company's manufacturing operations are highly centralized in Ohio, making them susceptible to disruption from natural disasters or other events, which could lead to substantial delays and decreased revenue. Non-compliance with extensive federal, state, and foreign regulations, including FDA regulations, anti-kickback statutes, and false claims acts, could result in substantial penalties, fines, injunctions, and even criminal prosecution. Specifically, promoting products for unapproved or "off-label" uses could lead to significant fines and penalties. Product liability claims arising from injuries or adverse events related to product use, even if meritless, could result in costly litigation, increased insurance rates, and reputational damage. Intellectual property rights may not provide meaningful commercial protection, enabling competitors to use similar technologies and reducing the company's competitive advantage. Litigation over intellectual property rights is common in the industry and can incur substantial costs and divert management attention. International operations expose the company to varying regulatory requirements, political and economic instability, and foreign currency exchange rate fluctuations, which could harm revenue and profitability. Changes in U.S. and international trade policies, such as tariffs, could disrupt supply chains and increase costs. Violations of anti-corruption laws like the FCPA could lead to severe criminal or civil sanctions. The use of artificial intelligence by employees or business partners could result in misuse or loss of proprietary information, violation of laws, or damage to reputation. The company has a history of net losses, including $11,448 thousand ¹⁷ in 2025, and may never become profitable, with an accumulated deficit of $413,203 thousand ⁴⁹ as of December 31, 2025. Goodwill of $234,781 thousand ⁵⁰ is subject to impairment testing, which could materially reduce assets and increase net loss. Inaccurate forecasting of revenue or product life cycles could lead to inventory-related charges, negatively affecting gross margins. The company is subject to credit risk from accounts receivable, particularly from international customers in economically challenging countries. Failure to comply with covenants in its Credit Agreement could result in an obligation to repay all outstanding debt and loss of access to borrowing capacity.

Management's message to shareholders emphasizes a passionate focus on healing patients affected by Afib and post-operative pain, driven by a strategy to expand treatment options through continued technological development, product offering expansion, clinical science investments, and global commercial growth. Key strategic priorities include new product and procedure innovation, such as the novel dual energy platform integrating PFA with Advanced RFA, for which a clinical trial is expected to be initiated in the coming year. Investments in clinical science are paramount, with ongoing landmark clinical trials like LeAAPS and BoxX-NoAF aimed at validating long-term results and supporting expanded regulatory indications. The company completed enrollment of 6,573 patients ³⁷ in the LeAAPS trial in July 2025 and the first patient enrollment in the BoxX-NoAF trial in October 2025, which aims to enroll up to 960 subjects ³⁹. Management also highlights building physician and societal relationships, providing comprehensive training and education through innovative methods like virtual proctoring and simulation models, and evaluating opportunistic acquisitions. The overall tone suggests a commitment to innovation and clinical validation to drive market adoption and address unmet patient needs, while acknowledging the competitive and regulatory complexities of the medical device industry.